Altimmune, Inc. Common Stock (ALT)
Altimmune, Inc. is a biotechnology company focused on developing immunotherapeutic solutions and vaccines for infectious diseases, cancer, and metabolic disorders. The company leverages innovative technology platforms to create treatments aiming to enhance immune responses and improve patient outcomes.
Company News
Faruqi & Faruqi is investigating potential claims against Altimmune after its stock price dropped 53.2% following disappointing Phase 2b MASH trial results for Pemvidutide, where statistical significance was not achieved.
The Schall Law Firm is pursuing a class action lawsuit against Altimmune for allegedly making false and misleading statements about its drug candidate Pemvidutide, which failed to achieve statistically significant results in its Phase 2B MASH trial.
Pfizer's experimental obesity drug danuglipron failed due to safety concerns, leading the company to consider acquiring Altimmune or Viking Therapeutics, which have promising obesity drug candidates. Pfizer may wait to see how its other obesity drug, PF-07976016, performs in clinical trials before making an acquisition decision.
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.